2022
DOI: 10.1039/d1cs00762a
|View full text |Cite
|
Sign up to set email alerts
|

Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation

Abstract: This tutorial review discusses the convergence of drug delivery systems and PROTACs, surveys the burgeoning PROTAC delivery strategies, summarizes their design principles, clarifies their challenges, and outlooks future translational opportunities.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
52
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 107 publications
(74 citation statements)
references
References 61 publications
0
52
0
Order By: Relevance
“…Since tumor immunotherapy is a multifactorial event, proteins in tumor cells, immune cells and tumor milieu can all be degraded by this novel technology. Future studies should develop more PROTAC molecules with preferable drug-like properties and expand their potency in immune modulation, while the following issues should be carefully taken into account: (i) More than “degrader”, PROTAC molecule can serve as an “intelligent switch” to program immune cells, which is exemplified by Park and co-workers [ 180 , 181 ]; (ii) certain targets had synchronous functions; therefore PROTAC molecules that simultaneously degraded two or more proteins are very promising [ 182 , 183 ]; (iii) E3 ligases CRBN and VHL are immuno-oncologic targets which can be degraded by homo-PROTAC strategies [ 184 , 185 , 186 ]; (iv) novel TPD strategies such as AUTAC, AbTAC, LYTAC and molecule glues have been developed to target extracellular and membrane proteins [ 187 , 188 ]; (v) advanced drug delivery systems (DDSs) including nanoparticles, polymetric micelles and liposomes can be leveraged to improve drug efficiency [ 189 , 190 ].…”
Section: Discussionmentioning
confidence: 99%
“…Since tumor immunotherapy is a multifactorial event, proteins in tumor cells, immune cells and tumor milieu can all be degraded by this novel technology. Future studies should develop more PROTAC molecules with preferable drug-like properties and expand their potency in immune modulation, while the following issues should be carefully taken into account: (i) More than “degrader”, PROTAC molecule can serve as an “intelligent switch” to program immune cells, which is exemplified by Park and co-workers [ 180 , 181 ]; (ii) certain targets had synchronous functions; therefore PROTAC molecules that simultaneously degraded two or more proteins are very promising [ 182 , 183 ]; (iii) E3 ligases CRBN and VHL are immuno-oncologic targets which can be degraded by homo-PROTAC strategies [ 184 , 185 , 186 ]; (iv) novel TPD strategies such as AUTAC, AbTAC, LYTAC and molecule glues have been developed to target extracellular and membrane proteins [ 187 , 188 ]; (v) advanced drug delivery systems (DDSs) including nanoparticles, polymetric micelles and liposomes can be leveraged to improve drug efficiency [ 189 , 190 ].…”
Section: Discussionmentioning
confidence: 99%
“…Although numerous PROTACs reviews have been published, most of them are either general introductions to PROTACs or applications in specific areas of therapy. 12,18,29–35 However, how to rationally design PROTACs and optimize the structure-activity relationship is a major problem and challenge in this field. Some excellent reviews have presented brief rules and lessons for PROTACs design and optimization.…”
Section: Introductionmentioning
confidence: 99%
“…PROTACs represent a new and very promising class of compounds to treat multiple chronic diseases and offer new pharmaceutical opportunities by targeting undruggable proteins. However, their physicochemical properties suspect minimal oral bioavailability, resulting in limited clinical effectiveness [ 3 , 8 , 38 ]. The investigated PROTAC ARCC-4 is a typical representative of this class.…”
Section: Discussionmentioning
confidence: 99%